Bruker completes €870M cash acquisition of ELITechGroup; expects $0.08-0.10 EPS accretion

BRUKER CORP

Purchase price of €870 million in cash for ELITech, excluding clinical chemistry business.
ELITech FY2023 revenue ~€150M with >80% consumables; systems include InGenius and BeGenius MDx platforms.
Remainder 2024 expected ELITech revenue ~$100M within Bruker, non-GAAP EBIT margins >20%.
Non-GAAP EPS accretion of $0.08-$0.10 for FY 2024 after acquisition financing costs.
ELITech to become Bruker Molecular Diagnostics within Microbiology & Infection Diagnostics division.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.